Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

536P - Incidence of fractures in TRK fusion cancer patients treated with larotrectinib


16 Sep 2021


ePoster Display


Clinical Research;  Targeted Therapy;  Rare Cancers

Tumour Site

Colon and Rectal Cancer;  Head and Neck Cancers


Theodore W. Laetsch


Annals of Oncology (2021) 32 (suppl_5): S583-S620. 10.1016/annonc/annonc699


T.W. Laetsch1, C.M. van Tilburg2, S. Kummar3, A. Dowlati4, K. Guiver5, M. Fellous6, N. Brega7, E. De La Cuesta8, A. Shurshalina8, A. Drilon9, D. Hong10

Author affiliations

  • 1 Cancer Center, The Children’s Hospital of Philadelphia / University of Pennsylvania, PA 19104 - Philadelphia/US
  • 2 Department Of Pediatric Oncology, Hematology, Immunology And Pulmonology, Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg/DE
  • 3 Department Of Medicine, Stanford Cancer Center, Stanford University, Palo Alto/US
  • 4 Department Of Medicine, University Hospitals Ahuja Medical Center, Cleveland/US
  • 5 Biostatistics, Bayer HealthCare Pharmaceuticals, Inc., Reading/GB
  • 6 Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Inc., Basel/CH
  • 7 Global Oncology Sbu, Bayer HealthCare Pharmaceuticals, Milan/IT
  • 8 Global Oncology Sbu, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 9 Early Drug Development Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 10065 - New York/US
  • 10 Division Of Cancer Medicine, MD Anderson Cancer Center, Houston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 536P


Serious fractures have been reported in patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer receiving non-selective TRK inhibitors (Frampton, Drugs 2021). Larotrectinib is a first-in-class, highly selective TRK inhibitor approved in over 40 countries for the treatment of adult and paediatric pts with TRK fusion cancer. Here we report the incidence of fractures in pts with cancer treated with larotrectinib.


Data on the incidence of fractures were pooled from three phase I/II trials of pts with solid and CNS tumours treated with larotrectinib monotherapy (NCT02122913, NCT02576431 and NCT02637687).


As of July 20, 2020, a total of 331 pts (214 adults, 117 paediatric) were included in this analysis. Treatment-emergent fractures of any grade occurred in 15 adults (7.0%) and 9 children (7.7%). Among adults, fractures occurred in the rib (5 pts), face, femur, foot, hip, vertebra (2 pts each), and fibula, neck, sternum, tibia and wrist (1 pt each), with 5 adults experiencing 2 fractures. Among children, fractures involved the wrist, ulna (2 pts each), femur, fibula, humerus, upper limb not otherwise specified and spinal compression (1 pt each). The majority of the fractures were attributed to trauma due to a fall or were tumour-related. No fractures were considered larotrectinib-related by the investigator, and no pts discontinued treatment due to a fracture (table). Table: 536P

Adult patients n=214 Paediatric patients n=117
Patients with fractures, n (%) 15 (7.0) 9 (7.7)
Total fractures, n 20 9
Grade 1 or 2 12 8
Grade 3 7 1
Grade 5 1 0
Larotrectinib-related fractures 0 0
Time to first fracture, months, median (range) 13.0 (0.9–45.8) 8.0 (0.9–40.5)
Treatment interruption due to fracture, n (%) 5 (33.0) 0
Treatment discontinuation due to fracture, n (%) 0 0
Associated events by fracture, n
Trauma 11§ 5
Tumour related 3§ 2
Stress fracture 1 1
Not reported 5 1

One grade 3 fracture was downgraded to grade 2 on day 83.Cervical vertebral fracture unrelated to larotrectinib.§One patient had two fractures: one fall-related fracture and one tumour-related fracture.


The incidence of fractures in oncology pts is estimated to be up to 18% in adults and 6% in children with solid tumours (FDA, 2021). Therefore, the incidence of fractures in pts treated with larotrectinib was within the expected range for pts with solid tumours. Fractures were mainly grade 1–2 and associated with trauma (fall) or were tumour-related. Additional data are warranted to assess the potential association between larotrectinib and skeletal fractures, including ongoing long-term follow-up in paediatric pts.

Clinical trial identification

NCT02122913, first posted April 25, 2014 NCT02637687, first posted December 22, 2015 NCT02576431, first posted October 25, 2015.

Editorial acknowledgement

Medical writing assistance was provided by Michael Sheldon of Scion, London, UK, supported by Bayer HealthCare Pharmaceuticals Inc.

Legal entity responsible for the study

Bayer HealthCare Pharmaceuticals and LOXO Oncology.


Bayer HealthCare Pharmaceuticals and LOXO Oncology.


T.W. Laetsch: Financial Interests, Personal, Advisory Role: Novartis, Cellectis, Bayer, Loxo, Lilly, Deciphera, Jumo Health, Y-mAbs Therapeutics; Financial Interests, Personal, Research Grant: Pfizer, Novartis, Bayer, Loxo, AbbVie, Amgen, Atara, Biotherapeutics, BMS, Lilly, Epizyme, GSK, Janssen, Jubilant Pharmaceuticals, Novella Clinical, Servier. C.M. van Tilburg: Financial Interests, Personal, Advisory Board: Bayer, Novartis. S. Kummar: Financial Interests, Personal, Advisory Role: Boehringer Ingelheim, Springworks Therapeutics, Varian, Bayer, Genome & Company, HarbourBiomed, Seagen, Mundibiopharma Ltd, Gilead,; Financial Interests, Personal, Other, Travel support: Bayer; Financial Interests, Personal, Other, Editor-in-Chief, Current Problems in Cancer: Elsevier. A. Dowlati: Financial Interests, Personal, Advisory Role: Takeda, Abbvie, Seattle Genetics, AstraZeneca, Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Loxo, Bayer, Incuron, Takeda, Regeneron, Tesaro, Amgen, Seattle genetics, Symphogen, Abbvie and Ipsen. K. Guiver: Financial Interests, Personal, Full or part-time Employment: Bayer. M. Fellous: Financial Interests, Personal, Full or part-time Employment: Bayer. N. Brega: Financial Interests, Personal, Full or part-time Employment: Bayer. E. De La Cuesta: Financial Interests, Personal, Full or part-time Employment: Bayer. A. Shurshalina: Financial Interests, Personal, Full or part-time Employment: Bayer. A. Drilon: Financial Interests, Personal, Advisory Role: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Onco; Financial Interests, Institutional, Research Grant: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar; Financial Interests, Personal, Royalties: Wolters Kluwer; Financial Interests, Personal, Other, Food/Beverage: Merck, Puma, Merus, Boehringer Ingelheim; Financial Interests, Personal, Other, CME homoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Medscape, Clinical Care Optio. D. Hong: Financial Interests, Personal, Research Grant: AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, Loxo Oncology, Merck, MedImmune, Mirati, MiRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfize; Financial Interests, Personal, Advisory Board: Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer, Genentech, GLG, Group H, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Seattle Genetics, Takeda, and Trieza Therapeutics; Financial Interests, Personal, Ownership Interest: Molecular Match (advisor), OncoResponse (founder), and Presagia Inc (advisor); Financial Interests, Personal, Other, Travel/accomadation: Loxo Oncology, MiRNA, ASCO, AACR, SITC, Genmab.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.